About GRI Bio, Inc. Common Stock
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Market Cap
$0.00B
Employees
4
Listed Since
April 24, 2023
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.gribio.comPhone
(619) 400-1171
Headquarters
2223 AVENIDA DE LA PLAYA
LA JOLLA, CA 92037
CIK
0001824293